Jens Zimmermann

Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

Marco Cicardi, Aleena Banerji, Francisco Bracho et al. · New England Journal of Medicine · 2010 · 554 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

Glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats

R. Schick, Jens Zimmermann, Thomas vorm Walde et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2003 · 151 citations

Medicine, Neuroscience, Pharmacology +17

Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

Pierre‐François Laterre, Peter Pickkers, Gernot Marx et al. · Intensive Care Medicine · 2021 · 92 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +15

A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

Christopher Geven, Alice Blet, Matthijs Kox et al. · BMJ Open · 2019 · 48 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)

Mahir Karakas, Dominik Jarczak, Martin Becker et al. · Biomolecules · 2020 · 28 citations · Full text

Medicine, Immunology, Pharmacotherapy +17